Canagliflozin (Hemihydrate): SGLT2 Inhibitor for Glucose Metabolism & Diabetes Research

Executive Summary: Canagliflozin (hemihydrate) is a rigorously characterized small molecule SGLT2 inhibitor (C24H26FO5.5S, MW 453.52) used for research on glucose homeostasis and renal glucose reabsorption inhibition [APExBIO Product Page]. It demonstrates high solubility in ethanol (≥40.2 mg/mL) and DMSO (≥83.4 mg/mL), but is insoluble in water. Quality control by HPLC and NMR ensures ≥98% purity. Recent yeast-based mTOR pathway screens confirm it does not inhibit mTOR/TOR1, clarifying its selectivity profile (Breen et al., 2025). The product is intended for research use in metabolic disorder and diabetes mellitus models, not for clinical or diagnostic purposes.

Biological Rationale

Canagliflozin (hemihydrate), also known as JNJ 28431754 hemihydrate, is classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This drug class targets renal glucose reabsorption mechanisms, a central pathway in glucose metabolism and diabetes mellitus research. SGLT2 is predominantly expressed in the proximal renal tubules, where it mediates ~90% of glucose reabsorption from the glomerular filtrate. Inhibiting SGLT2 results in increased urinary glucose excretion, leading to lower blood glucose levels. This mechanistic rationale underpins the use of Canagliflozin (hemihydrate) in studies of metabolic disorders and glucose homeostasis pathways [APExBIO]. For a broader context, see this article, which surveys translational and experimental boundaries of SGLT2 inhibitors; the present article updates with detailed selectivity data and negative mTOR findings.

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) functions as a competitive, reversible inhibitor of SGLT2. By binding to SGLT2 in the renal proximal tubule, it blocks the reabsorption of filtered glucose, causing glycosuria and reducing systemic glucose levels. This mechanism is independent of insulin signaling. The compound does not interact with mTOR signaling, as demonstrated in recent drug-sensitized yeast assays (Breen et al., 2025). For a mechanistic deep dive, see this review, which synthesizes biological rationale and translational strategies; here, we further clarify the compound’s lack of mTOR activity and experimental usage parameters.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) exhibits ≥98% purity as confirmed by HPLC and NMR under standard laboratory conditions (APExBIO QC Data, product page).
• Compound is insoluble in water, but dissolves to ≥40.2 mg/mL in ethanol and ≥83.4 mg/mL in DMSO at room temperature (APExBIO datasheet, product page).
• Does not inhibit mTOR/TOR1 activity in yeast growth-based assays at concentrations up to 100 μM (Breen et al., 2025, DOI).
• Inhibits renal glucose reabsorption by blocking SGLT2 in the proximal tubule, increasing urinary glucose excretion (FDA Label, FDA).
• Recommended storage at -20°C; solutions should be used promptly and not stored long-term to maintain efficacy (APExBIO protocol, product page).

For a comparative analysis of SGLT2 inhibitors and their differentiation from mTOR pathway compounds, see this technical review, which this article extends with updated evidence on selectivity and workflow integration.

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is a validated tool compound for:

• Investigating renal glucose reabsorption and systemic glucose homeostasis pathways.
• Modeling diabetes mellitus and metabolic disorders in vitro and in vivo.
• Screening for SGLT2-dependent phenotypes in cellular and animal models.

It is not suitable for:

• Direct mTOR pathway inhibition or studies requiring mTOR/TOR1 modulation (Breen et al., 2025, DOI).
• Clinical or diagnostic use.
• Long-term storage in solution, as stability may be compromised (APExBIO).

For unmatched specificity in SGLT2 inhibition and advanced protocol suggestions, see this article; the current work extends with a focus on negative mTOR data and workflow parameters for research reproducibility.

Common Pitfalls or Misconceptions

• Misconception: Canagliflozin (hemihydrate) inhibits mTOR signaling.
  Fact: No evidence for mTOR/TOR1 inhibition was detected in drug-sensitized yeast assays (Breen et al., 2025).
• Misuse: Application in clinical/diagnostic contexts.
  Fact: This compound is intended solely for research use (APExBIO).
• Storage error: Long-term storage of solutions.
  Fact: Solutions should be prepared fresh and used promptly to ensure compound integrity.
• Solubility assumption: Assumes water solubility.
  Fact: The compound is insoluble in water; use ethanol or DMSO for stock solutions (APExBIO datasheet).

Workflow Integration & Parameters

Canagliflozin (hemihydrate, APExBIO C6434) is supplied as a solid with ≥98% purity. For in vitro studies, dissolve in DMSO (≥83.4 mg/mL) or ethanol (≥40.2 mg/mL). For in vivo research, appropriately dilute stock solutions to achieve target dosages. Store the dry compound at -20°C; ship on blue ice for temperature regulation. Avoid prolonged storage of prepared solutions. Quality is verified by HPLC and NMR before distribution. For research designs requiring SGLT2 inhibition without off-target mTOR effects, this compound is validated and highly specific. Refer to this technical workflow guide for experimental design tips; the present article adds critical boundaries and negative pathway data for robust planning.

Conclusion & Outlook

Canagliflozin (hemihydrate) from APExBIO is a high-purity, well-characterized SGLT2 inhibitor, ideal for glucose metabolism and diabetes mellitus research. It offers strong selectivity for SGLT2 with robust negative data for mTOR/TOR1 inhibition, ensuring pathway-specific study design. Careful workflow integration and awareness of compound boundaries enable reproducible, high-fidelity research in metabolic disorders. For complete technical details and ordering, see the product page.